Antonio Marzo

Summary

Affiliation: Clinical Pharmacology Unit
Country: Switzerland

Publications

  1. doi Critical considerations into the new EMA guideline on bioequivalence
    Antonio Marzo
    Clinical Pharmacology Unit, I P A S SA, Ligornetto, Switzerland
    Arzneimittelforschung 61:207-20. 2011
  2. ncbi Open questions on bioequivalence: the case of multiple peak phenomenon
    Antonio Marzo
    I P A S S A, Clinical Pharmacology Unit, Via Mastri 36, 6853 Ligornetto, Switzerland
    J Pharm Pharmacol 56:281-2. 2004
  3. ncbi Development steps of pharmacokinetics: a perspective on bioanalytical methods and bioequivalence
    Antonio Marzo
    Clinical Pharmacology Unit, Institute for Pharmacokinetic and Analytical Studies SA, Via Mastri 36, 6853 Ligornetto Switzerland
    Curr Clin Pharmacol 7:328-32. 2012
  4. ncbi Tandem mass spectrometry (LC-MS-MS): a predominant role in bioassays for pharmacokinetic studies
    Antonio Marzo
    I P A S S A Institute for Pharmacokinetic and Analytical Studies, Ligornetto, Switzerland
    Arzneimittelforschung 57:122-8. 2007
  5. ncbi Open questions on bioequivalence: an updated reappraisal
    Antonio Marzo
    IPAS SA, Via Mastri, Ligornetto, Switzerland
    Curr Clin Pharmacol 2:179-89. 2007
  6. doi Pharmacokinetics of isoxsuprine hydrochloride administered orally and intramuscularly to female healthy volunteers
    Antonio Marzo
    Clinical Pharmacology Unit, I P A S SA, Via Mastri 36, 6853 Ligornetto, Switzerland
    Arzneimittelforschung 59:455-60. 2009
  7. doi Pharmacokinetics and pharmacodynamics of ritodrine hydrochloride administered orally and intramuscularly to female healthy volunteers
    Antonio Marzo
    IPAS SA, Ligornetto, Switzerland
    Arzneimittelforschung 60:510-8. 2010
  8. ncbi Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity
    Antonio Marzo
    IPAS SA, Via Mastri 36, 6853 Ligornetto TI, Switzerland
    Pharmacol Res 50:77-85. 2004
  9. ncbi The degree of predictivity in pilot studies on six subjects in bioequivalence trials
    Antonio Marzo
    Clinical Pharmacology Unit, IPAS SA, Via Mastri 36, 6853, Ligornetto, Switzerland
    Pharmacol Res 49:283-6. 2004
  10. ncbi Open questions on bioequivalence: what about the time interval between two consecutive trials?
    Antonio Marzo
    I P A S S A, Ligornetto, Switzerland
    Arzneimittelforschung 57:505-6. 2007

Collaborators

Detail Information

Publications18

  1. doi Critical considerations into the new EMA guideline on bioequivalence
    Antonio Marzo
    Clinical Pharmacology Unit, I P A S SA, Ligornetto, Switzerland
    Arzneimittelforschung 61:207-20. 2011
    ....
  2. ncbi Open questions on bioequivalence: the case of multiple peak phenomenon
    Antonio Marzo
    I P A S S A, Clinical Pharmacology Unit, Via Mastri 36, 6853 Ligornetto, Switzerland
    J Pharm Pharmacol 56:281-2. 2004
  3. ncbi Development steps of pharmacokinetics: a perspective on bioanalytical methods and bioequivalence
    Antonio Marzo
    Clinical Pharmacology Unit, Institute for Pharmacokinetic and Analytical Studies SA, Via Mastri 36, 6853 Ligornetto Switzerland
    Curr Clin Pharmacol 7:328-32. 2012
    ....
  4. ncbi Tandem mass spectrometry (LC-MS-MS): a predominant role in bioassays for pharmacokinetic studies
    Antonio Marzo
    I P A S S A Institute for Pharmacokinetic and Analytical Studies, Ligornetto, Switzerland
    Arzneimittelforschung 57:122-8. 2007
    ..This paper analyses the growing development of the LC-MS-MS technique and compares four couples of methods validated with HPLC or GC versus LC-MS-MS, giving analytical details of the two approaches...
  5. ncbi Open questions on bioequivalence: an updated reappraisal
    Antonio Marzo
    IPAS SA, Via Mastri, Ligornetto, Switzerland
    Curr Clin Pharmacol 2:179-89. 2007
    ..An appropriate approach to the "open questions" is a requisite to achieve a clearly defined bioequivalence/bioinequi-valence conclusion...
  6. doi Pharmacokinetics of isoxsuprine hydrochloride administered orally and intramuscularly to female healthy volunteers
    Antonio Marzo
    Clinical Pharmacology Unit, I P A S SA, Via Mastri 36, 6853 Ligornetto, Switzerland
    Arzneimittelforschung 59:455-60. 2009
    ..This was an expected finding attributable to the stimulating activity of beta-adrenergic receptors. The tolerability of isoxsuprine proved to be very good with all the four administrations performed...
  7. doi Pharmacokinetics and pharmacodynamics of ritodrine hydrochloride administered orally and intramuscularly to female healthy volunteers
    Antonio Marzo
    IPAS SA, Ligornetto, Switzerland
    Arzneimittelforschung 60:510-8. 2010
    ..o. absorption of ritodrine hydrochloride was linearly related with the doses administered in the 10-30 mg range. The pharmacodynamic parameters evaluated complied with the mechanism of action of this drug...
  8. ncbi Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity
    Antonio Marzo
    IPAS SA, Via Mastri 36, 6853 Ligornetto TI, Switzerland
    Pharmacol Res 50:77-85. 2004
    ....
  9. ncbi The degree of predictivity in pilot studies on six subjects in bioequivalence trials
    Antonio Marzo
    Clinical Pharmacology Unit, IPAS SA, Via Mastri 36, 6853, Ligornetto, Switzerland
    Pharmacol Res 49:283-6. 2004
    ....
  10. ncbi Open questions on bioequivalence: what about the time interval between two consecutive trials?
    Antonio Marzo
    I P A S S A, Ligornetto, Switzerland
    Arzneimittelforschung 57:505-6. 2007
    ..This appears to be an additional open question on bioequivalence...
  11. ncbi Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers
    Antonio Marzo
    I P A S Institute for Pharmacokinetic and Analytical Studies S A, Ligornetto, Switzerland
    Arzneimittelforschung 52:233-42. 2002
    ..The main difference in the pharmacokinetics of the two compounds is the conversion from pro-drug to the active metabolite which is faster with zofenopril...
  12. ncbi Bioequivalence of ticlopidine hydrochloride administered in single dose to healthy volunteers
    Antonio Marzo
    IPAS SA, Via Mastri 36, 6853 Ligornetto, Switzerland
    Pharmacol Res 46:401-7. 2002
    ..According to guidelines operating in Europe, the test formulation of ticlopidine hydrochloride can be declared bioequivalent with the reference, both formulations in 250mg tablets...
  13. ncbi Enantioselective analytical methods in pharmacokinetics with specific reference to genetic polymorphic metabolism
    Antonio Marzo
    IPAS SA, Via Mastri 36, 6853 Ligornetto, Switzerland
    J Biochem Biophys Methods 54:57-70. 2002
    ..It includes a specific discussion for the genetic polymorphic metabolism involving stereogenic centres...
  14. ncbi Pharmacokinetic behaviour of antithrombin III following intravenous infusion in healthy volunteers
    Antonio Marzo
    IPAS Institute for Pharmacokinetic and Analytical Studies S A, Clinical Pharmacology Unit, Ligornetto, Switzerland
    Arzneimittelforschung 52:187-93. 2002
    ..The authors conclude that the nanofiltration step neither affects at all the pharmacokinetics/pharmacodynamics nor the safety of the formulation investigated...
  15. ncbi Bioassay of safinamide in biological fluids of humans and various animal species
    Lorenzo Dal Bo
    Arzneimittelforschung 56:814-9. 2006
    ..Main pharmacokinetic results obtained in various Phase I trials on healthy volunteers are briefly reported...
  16. ncbi Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients
    Davide Soldini
    Division of Nephrology, Ospedale Regionale di Bellinzona e Valli, 6500, Bellinzona TI, Switzerland
    Eur J Clin Pharmacol 60:859-64. 2005
    ..N-acetylcysteine (NAC) is a mucolytic agent with anti-oxidant properties. It might have potential positive effects in renal patients and, therefore, its pharmacokinetics and safety in haemodialysis was investigated...
  17. ncbi Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition
    Carlo Cattaneo
    Newron Pharmaceuticals S p A, Via Ludovico Ariosto 21, 20091 Gerenzano, Italy
    Clin Neuropharmacol 26:213-7. 2003
    ..These results suggest that dietary restrictions for food with high tyramine content should not be required under safinamide treatment...
  18. ncbi Bioequivalence study of fluoxetine hydrochloride in healthy volunteers
    Thomas Keller
    Mepha Ltd, Aesch, BL, Switzerland
    Arzneimittelforschung 55:491-7. 2005
    ..In conclusion, the present trial has demonstrated bioequivalence of the test and the reference formulation, both consisting of fluoxetine hydrochloride dispersible tablets...